Your voice in the tumor board: study tests if patient reports lead to better cancer treatment

NCT ID NCT07671937

Not yet recruiting Knowledge-focused Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study will include about 2,748 people with breast, gynecologic, or pancreatic cancer. Researchers want to see if adding patient-reported outcomes—like symptoms, preferences, and travel distance—to tumor board discussions helps doctors make better treatment decisions. The goal is to reduce treatment delays and side effects while improving patient experience.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: patient-reported outcomes (ePROs) integrated into tumor board discussions
What this could lead to: If successful, this could show that including patient feedback in treatment planning leads to better-tailored cancer care and fewer treatment side effects.
What could go wrong: This is an early-stage behavioral study, not a drug trial. It may not change actual treatment outcomes, and results may vary across different hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm endometrial cancer female reproductive organ cancer malignant pancreatic neoplasm ovarian cancer pancreatic neoplasm uterine corpus cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER CORPUS UTERI CANCER OTHER FEMALE GENITAL MALIGNANT NEOPLASMS OVARY CANCER PANCREAS CANCER

Contacts and locations

Locations

University of Alabama at Birmingham

Birmingham, Alabama, 35294, United States
University of California Los Angeles (UCLA)

Los Angeles, California, 90404, United States
University of Oklahoma (OU) Health Campus

Oklahoma City, Oklahoma, 73126-0901, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.